Open Journal of Depression

Volume 2, Issue 4 (November 2013)

ISSN Print: 2169-9658   ISSN Online: 2169-9674

Google-based Impact Factor: 1.69  Citations  

Cognitive and Psychosocial Improvements Following Aripiprazole Augmentation of SSRI Antidepressant Therapy in Treatment Refractory Depression: A Pilot Study

HTML  Download Download as PDF (Size: 304KB)  PP. 45-53  
DOI: 10.4236/ojd.2013.24010    3,982 Downloads   7,855 Views  Citations

ABSTRACT

Functional impairments are a common concern for individuals with major depressive disorder (MDD) that does not resolve with initial antidepressant treatment. Such concerns include cognitive difficulties, such as impaired executive functions, which can be particularly disruptive to daily function. There is a need to evaluate potential augmentation strategies for depressed individuals who do not adequately respond to initial antidepressant treatment. Aripiprazole is an FDA-approved adjunctive treatment to antidepressants for MDD, and because of its effect on both dopaminergic and serotonergic systems, may be of particular benefit to cognitive functioning. This study evaluated depressive symptom severity, cognitive function, and psychosocial function before and after six weeks of open-label aripiprazole augmentation treatment in patients with MDD who did not fully respond to selective serotonin reuptake inhibitor treatment. Participants endorsed difficulty with concentration and decision-making at study entry. Significant decreases were observed for depressive symptoms, and significant increases were found in executive function measures and measures of psychosocial function and quality of life. These preliminary data suggest that aripiprazole augmentation may yield functional benefits when used as an adjunctive treatment in MDD, and support the need for further investigation of aripiprazole and other augmentation strategies to specifically evaluate functional outcomes in MDD.

Share and Cite:

Greer, T. , Sunderajan, P. , Grannemann, B. & Trivedi, M. (2013). Cognitive and Psychosocial Improvements Following Aripiprazole Augmentation of SSRI Antidepressant Therapy in Treatment Refractory Depression: A Pilot Study. Open Journal of Depression, 2, 45-53. doi: 10.4236/ojd.2013.24010.

Cited by

[1] IMPLICATIONS OF COGNITIVE IMPAIRMENT ON SEVERAL ASPECTS OF FUNCTIONALITY AND QUALITY OF LIFE IN MAJOR DEPRESSED PATIENTS.
Journal of Evidence …, 2022
[2] Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker …
2021
[3] ВЛИЯНИЕ КОГНИТИВНЫХ НАРУШЕНИЙ ПРИ РЕКУРРЕНТНОЙ ДЕПРЕССИИ НА СОЦИАЛЬНОЕ ФУНКЦИОНИРОВАНИЕ БОЛЬНЫХ В РЕМИССИИ
2019
[4] ВЛИЯНИЕ КОГНИТИВНЫХ ФУНКЦИЙ НА КАЧЕСТВО ЖИЗНИ ПРИ РЕМИССИИ РЕКУРРЕНТНОЙ ДЕПРЕССИИ
2019
[5] Cognitive functions effect on quality of life during remission of recurrent depression
2019
[6] Cognitive function in a randomized trial of evolocumab
2017
[7] Implications of cognitive impairments onfunctional outcomes in major depressive disorder
Cognitive Impairment in Major Depressive Disorder: Clinical Relevance, Biological Substrates, and Treatment Opportunities, 2016
[8] Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management
Focus, 2016
[9] Implications of cognitive impairments on functional outcomes in major depressive disorder
2016
[10] Depressione e cognitività
2016

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.